Product/Composition:- | Cefuroxime (2nd Gen) Powder for Suspension |
---|---|
Strength:- | 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL |
Form:- | Powder for Suspension |
Reference Brands:- | Ceftin, Zinacef(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cefuroxime suspension inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis and death. It effectively treats respiratory, urinary, and skin infections. Benefits include easy oral administration, rapid bacterial eradication, and broad-spectrum activity, making it suitable for pediatric and outpatient use for common bacterial infections.
Cefuroxime suspension is approved in the EU and US for treating respiratory, urinary, and skin infections. In the EU, brands like Zinacef are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its widespread use and safety profile, strict regulations on labeling, dosing, and usage are enforced. For expert assistance with dossier preparation, compliance, and registration, visit PharmaTradz. We support seamless market access ensuring adherence to European and American standards for effective antimicrobial therapy.